Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
As nations push for more ambition at climate talks, chairman says they may get it - 26 Tire Brands Reasonable for Seniors
- 3The Most Moving TED Talks You Want to Watch
- 4The 15 Most Rousing TED Chats on Self-awareness
- 5Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree
- Vote in favor of your Number one method for praising a birthday
- Everything to know about NASA's moon mission launching this week
- 5 Home Improvement Styles: Decision in favor of Your #1
- Nearly half of reindeer have been wiped out and armadillos are in Iowa. Here’s how animals are weathering warming holidays
- Man who grabbed Ariana Grande at 'Wicked: For Good' premiere also rushed Katy Perry onstage this year. Who is he and why is he doing this?
- The 10 Most Noteworthy Games in History
- Countdown begins for long-awaited Artemis II moon mission
- Language Learning Applications for Voyagers
- Step by step instructions to Figure out the Natural Effect of 5G Pinnacles
